Search Results for "calcium"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for calcium. Results 31 to 40 of 41 total matches.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
and
torsades de pointes.8
DRUG INTERACTIONS — Coadministration of antacids
or products containing calcium ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
de pointes. Concurrent use of
ozanimod with both a heart rate-lowering calcium
channel blocker ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
or products containing aluminum, calcium,
magnesium, or iron can decrease absorption of
doxycycline ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
INTERACTIONS — Coadministration of antacids
or oral products containing calcium, magnesium,
or iron can ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
impairment: CrCl 20 mg/day use cautiously
20-25%
40-45%
1083.10
Pitavastatin calcium ...
View the Comparison Table: Some Lipid-Lowering Drugs
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
(e.g., beta
blockers, calcium channel
blockers)
No adequate studies
in pregnant women ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
), a synthetic
neuronal N-type calcium channel blocker, is
administered intrathecally via a programmable ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
.
Orlistat increases oxalate absorption and may
increase the risk of developing calcium oxalate
kidney ...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight...
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
release
of the excitatory neurotransmitter glutamate from
PQ-type voltage-gated calcium channels ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
properties due to blockade of calcium channels; it is
also thought to reduce visceral hypersensitivity ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction